» Articles » PMID: 35806320

Omicron BA.2 Lineage, the "Stealth" Variant: Is It Truly a Silent Epidemic? A Literature Review

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Jul 9
PMID 35806320
Authors
Affiliations
Soon will be listed here.
Abstract

The epidemic curve of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is silently rising again. Worldwide, the dominant SARS-CoV-2 variant of concern (VOC) is Omicron, and its virological characteristics, such as transmissibility, pathogenicity, and resistance to both vaccine- and infection-induced immunity as well as antiviral drugs, are an urgent public health concern. The Omicron variant has five major sub-lineages; as of February 2022, the BA.2 lineage has been detected in several European and Asian countries, becoming the predominant variant and the real antagonist of the ongoing surge. Hence, although global attention is currently focused on dramatic, historically significant events and the multi-country monkeypox outbreak, this new epidemic is unlikely to fade away in silence. Many aspects of this lineage are still unclear and controversial, but its apparent replication advantage and higher transmissibility, as well as its ability to escape neutralizing antibodies induced by vaccination and previous infection, are rising global concerns. Herein, we review the latest publications and the most recent available literature on the BA.2 lineage of the Omicron variant.

Citing Articles

SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies.

Alhamlan F, Al-Qahtani A Int J Mol Sci. 2025; 26(3).

PMID: 39941026 PMC: 11818319. DOI: 10.3390/ijms26031263.


RNA barcode segments for SARS-CoV-2 identification from HCoVs and SARSr-CoV-2 lineages.

You C, Jiang S, Ding Y, Ye S, Zou X, Zhang H Virol Sin. 2024; 39(1):156-168.

PMID: 38253258 PMC: 10877444. DOI: 10.1016/j.virs.2024.01.006.


No Association between SARS-CoV-2 Infection and the Polymorphism of the Toll-like Receptor 7 () Gene in Female Population.

Zayed M, Kim Y, Lee C, Jeong B Diagnostics (Basel). 2023; 13(23).

PMID: 38066751 PMC: 10706783. DOI: 10.3390/diagnostics13233510.


Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared.

Parums D Med Sci Monit. 2023; 29:e942960.

PMID: 37908161 PMC: 10626992. DOI: 10.12659/MSM.942960.


Trends in SARS-CoV-2 clinically confirmed cases and viral load in wastewater: A critical alignment for Padua city (NE Italy).

Baldovin T, Amoruso I, Fonzo M, Bertoncello C, Groppi V, Pitter G Heliyon. 2023; 9(10):e20571.

PMID: 37822618 PMC: 10562905. DOI: 10.1016/j.heliyon.2023.e20571.


References
1.
Fowle N, Garrett B, Floyd O, Collins J, Krasnow A, Islas M . University-Associated SARS-CoV-2 Omicron BA.2 Infections, Maricopa County, Arizona, USA, 2022. Emerg Infect Dis. 2022; 28(7):1520-1522. PMC: 9239890. DOI: 10.3201/eid2807.220470. View

2.
Fonager J, Bennedbaek M, Bager P, Wohlfahrt J, Ellegaard K, Ingham A . Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022. Euro Surveill. 2022; 27(10). PMC: 8915403. DOI: 10.2807/1560-7917.ES.2022.27.10.2200181. View

3.
Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M . LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022; 39(7):110812. PMC: 9035363. DOI: 10.1016/j.celrep.2022.110812. View

4.
Zou J, Kurhade C, Xia H, Liu M, Xie X, Ren P . Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2. Nat Commun. 2022; 13(1):2956. PMC: 9135681. DOI: 10.1038/s41467-022-30580-5. View

5.
Chemaitelly H, Ayoub H, Almukdad S, Coyle P, Tang P, Yassine H . Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun. 2022; 13(1):3082. PMC: 9163167. DOI: 10.1038/s41467-022-30895-3. View